Denali Therapeutics (DNLI) reported accelerating launch momentum for its first approved Transport Vehicle therapy, Avlayah, and provided updated clinical and regulatory milestones for its broader pipeline during a presentation at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday.
Avlayah, also known as DNL126 or ifoctasen, treats Hunter syndrome and replaced ELAPRASE as the standard of care for the rare disease. Denali generated approximately $3.6 million in second-quarter revenue from the therapy and guided for $10 million to $12 million in the third quarter of 2024. The company has secured commercial coverage for more than half of eligible lives and 14 state Medicare programs. Management targeted converting all 47 patients enrolled in Phase I/II trials to commercial treatment by the end of 2024.
The total addressable market for Avlayah is estimated at roughly 2,000 patients globally, split across the U.S., Europe, and the rest of the world. In the U.S., Denali aims to treat 375 of an estimated 500 pediatric patients, representing about 75% of the eligible population. Hunter syndrome affects roughly 70% of metachromatic leukodystrophy patients with some form of neurologic dysfunction, and up to 95% when hearing impairment is included. Approximately 70% of diagnosed Hunter syndrome patients present with neuronopathic disease, which carries an average life expectancy of around age 15 on prior standard care.
Beyond Avlayah, Denali advanced its Sanfilippo A program, XAFI (DNL593), toward a potential biologics license application in 2027. In an initial eight-patient dose-finding cohort, cerebrospinal fluid heparan sulfate fell by more than 80%, and six of seven patients achieved normalized GM3 biomarker levels. The company also highlighted preclinical work on TREM2-targeting antibodies, noting robust biomarker activity at roughly one-sixtieth of the naked antibody dose in human studies.
Clinical readouts for Denali’s Alzheimer’s programs—OTV:Abeta and OTV:MAPT—are expected in 2026, while data from the frontotemporal dementia (FTD-GRN) program is projected for the first half of 2027. The COMPASS trial is evaluating adult and pediatric label expansion, with Cohort A enrolling patients aged 2 to 6 focused on neurologic manifestations, and Cohort B covering ages 2 to 26 to establish comparability with ELAPRASE for a potential adult indication.
On the operational side, Denali announced it had onshored manufacturing to its Salt Lake City commercial facility four years prior, moving away from outsourced production models. The prescriber base remains concentrated among approximately 80 to 100 centers of excellence in the U.S., many of which participated in early clinical trials.
Shares of Denali have risen 48.63% over the past year and 27.74% year-to-date, according to InvestingPro data. The company holds a market capitalization of $3.4 billion and maintains a current ratio of 8.37. Wall Street analysts maintain a strong buy consensus, with price targets ranging from $27 to $42. Guidance for the third and fourth quarters of 2024 will be followed by a full outlook reassessment in 2027.
